Humacyte Announces FDA Acceptance Of Ind For First-In-Human Clinical Study Of Ctev For Coronary Artery Bypass Grafting
HUMA•Source notes
Source text: ID:nGNX3Gkn6z
Further company coverage: HUMA.O
FDA accepts IND for first-in-human study
July 27 (Reuters) - Humacyte Inc HUMA.O:
- Humacyte announces FDA acceptance of IND for first-in-human clinical study of CTEV for coronary artery bypass grafting
- Humacyte - to initiate Phase 2a CTEV study in CABG this quarter
Related News
Willis says data center insurance capacity nears US $15 billion, urges risk-led buying
WTW•
Citizens Community Bancorp, Inc. Reports Second Quarter 2026 Earnings Of $0.11 Per Share Board Approves Quarterly Dividend At $0.105 Per Share
CZWI•
